-
Post date
April 19, 2022
-
Posted by
Kieran Robertson
-
Posted in
FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, filament health neo, Filament Health Trials, filament stock, Mushrooms, Natural Psychedelic, natural psychedelic extraction, natural psychedelics, Patent, patent issue, psilocybin, Psychedelics, Psyence Group, psyg.c
-
Post date
March 23, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelic companies, best psychedelics companies, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, invest in psychedelics, mushroom, Mushrooms, Patent, Patent Application, psilocybin, psychedelic formulations, psychedelic market, Psychedelics
-
Post date
March 23, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelic companies, best psychedelics companies, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, invest in psychedelics, mushroom, Mushrooms, Patent, Patent Application, psilocybin, psychedelic formulations, psychedelic market, Psychedelics
-
Post date
January 14, 2022
-
Posted by
Kieran Robertson
-
Posted in
clinical trial, clinical trials psilocybin 2021, Mushrooms, NBIO-01, NUMI.T, Numinus Health, numinus stock, Numinus Wellness Inc., Numinus Wellness Inc. (NUMI.T), Patent, Patent Application, patent pending, process technology, psilocybin, psychedelic-assisted psychotherapies, Psychedelics
-
Post date
August 17, 2021
-
Posted by
Piers Eaton
-
Posted in
Biotech, board of directors, cash, cybin, Eaton, financials, First Quarter, Health Science, International Patent, Mushrooms, Patent, PCT, Psychedelics, Q1, Rights Plan, Shareholder Rights, Theresa Firestone
